Molly Crowe
Overview
Explore the profile of Molly Crowe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davis M, French R, Crowe M, Abrams M, Edwards G, Aronowitz S, et al.
J Addict Med
. 2025 Feb;
PMID: 39898531
Objective: The aim of the study was to explore hospitalized patient priorities for effective communication and care in opioid use disorder (OUD). Methods: In this qualitative descriptive study, we conducted...
2.
Toto R, Delgado E, Ketterer T, Berner E, Landau S, Crowe M, et al.
AEM Educ Train
. 2024 Oct;
8(5):e11038.
PMID: 39479531
Background: Emergency physicians care for most children presenting to U.S. emergency departments (EDs). Pediatric exposure during emergency medicine (EM) residency can be variable and critically ill children are rarely encountered....
3.
French R, Davis M, Aronowitz S, Crowe M, Abrams M, Edwards G, et al.
Addict Sci Clin Pract
. 2023 Jun;
18(1):41.
PMID: 37355639
Background: Extant literature is limited on adoption of evidence-based harm reduction strategies in hospitals. We explored patient perceptions of incorporating harm reduction supplies and education in hospital care with patients...
4.
Lowenstein M, Abrams M, Crowe M, Shimamoto K, Mazzella S, Botcheos D, et al.
Drug Alcohol Depend
. 2023 May;
248:109915.
PMID: 37207615
Purpose: Low-barrier treatment is an emerging strategy for opioid use disorder (OUD) care that prioritizes access to evidence-based medication while minimizing requirements that may limit treatment access in more traditional...
5.
Ignatowska-Jankowska B, Baillie G, Kinsey S, Crowe M, Ghosh S, Owens R, et al.
Neuropsychopharmacology
. 2015 Jun;
40(13):2948-59.
PMID: 26052038
The CB1 receptor represents a promising target for the treatment of several disorders including pain-related disease states. However, therapeutic applications of Δ(9)-tetrahydrocannabinol and other CB1 orthosteric receptor agonists remain limited...